Transmissible spongiform encephalopathies (TSEs), or prion diseases, are fatal neurodegenerative disorders characterised by long incubation period, short clinical duration, and transmissibility to susceptible species. Neuronal loss, spongiform changes, gliosis and the accumulation in the brain of the misfolded version of a membrane-bound cellular prion protein (PrP C ), termed PrP TSE , are diagnostic markers of these diseases. Compelling evidence links protein misfolding and its accumulation with neurodegenerative changes. Accordingly, several mechanisms of prion-mediated neurotoxicity have been proposed. In this paper, we provide an overview of the recent knowledge on the mechanisms of neuropathogenesis, the neurotoxic PrP species and the possible therapeutic approaches to treat these devastating disorders.
Animal and human prion diseases
The term prion was originally coined by S.B. Prusiner to denote a small proteinaceous infectious particle, which is resistant to most procedures that inactivate nucleic acids (Ref. 1) . Prion diseases or transmissible spongiform encephalopathies (TSEs) are fatal neurodegenerative disorders affecting humans and animals ( Fig. 1) . Human TSEs are often categorised with other protein misfolding neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease, Huntington's disease, fronto-temporal dementia and amyotrophic lateral sclerosis (Ref. 2) . These diseases share a common mechanism that involves a conformational change in the structure of the diseaseimplicated protein, leading to self-replicating propagation and subsequent pathological changes within the central nervous system (CNS). However, only TSEs are known to cause infections of epidemic proportions in humans (kuru) and animals [bovine spongiform encephalopathy (BSE)], and be endemically present in domestic (scrapie) and wild animals [chronic wasting disease (CWD)] (Fig. 1) .
Human TSEs can be subdivided into three aetiological groups: sporadic, genetic and environmentally acquired (i.e. infectious). Sporadic Creutzfeldt-Jakob disease (sCJD) is the most common form, occurring without any obvious cause with a frequency of 1 case per million people per year worldwide (Ref. 3) . Sporadic fatal insomnia (sFI) is a very rare disease described in only approximately 2 dozen cases so far (Refs 3, 4). The spectrum has been recently expanded to include variably protease-sensitive prionopathy, a rare sporadic condition recognised in a small number of patients, with certain features resembling Gerstmann-Sträussler-Scheinker syndrome (GSS) (Refs 5, 6, 7, 8) . The genetic forms represent 10-15% of all TSE cases and include familial CJD (fCJD), GSS and fatal familial insomnia (FFI) (Refs 9, 10). These diseases are inherited in an autosomal dominant fashion and are associated with more than 30 pathogenic mutations in the prion protein gene (PRNP) (Ref. 11) . The infectious forms include variant CJD (vCJD), presumably resulting from dietary exposure to BSE (Ref. 12) , iatrogenic CJD (iCJD) (Ref. 13) , and kuru, an almost extinct disease described in cannibalistic tribes of New Guinea ( Refs 14, 15, 16, 17) . iCJD has been linked to therapeutic treatments with human pituitary hormones (growth hormone and gonadotropin), dura mater, cornea or pericardial grafts unknowingly sourced from CJD-afflicted individuals, and to rare neurosurgical procedures performed with inadequately decontaminated instruments previously used on CJD patients (Refs 13, 18) . Recently, the transmission of vCJD has been reported in four instances through the therapeutic use of nonleukoreduced red blood cell concentrates ( Refs 13, 19, 20, 21, 22) .
Each form of human TSE results in a distinctive phenotype characterised by differences in the age of onset, variability in clinical symptoms, brain pathology and disease duration, and by different PrP TSE distribution and deposition patterns [reviewed in (Refs 3, 8, 10, 15, 16, 17, 23) ]. The molecular mechanisms of TSE phenotypic heterogeneity are not fully understood, although polymorphisms in the host PRNP gene influence the phenotypic differences and individual susceptibility to certain forms of the disease ( Refs 24, 25, 26, 27, 28, 29, 30, 31) . These polymorphisms also partially explain the origin of biochemically distinct PrP TSE conformers substantiating the existence of prion strains in humans ( Refs 32, 33, 34) and animals ( Refs 35, 36, 37) .
In animals, TSEs manifest, among other forms, as scrapie in sheep and goat, BSE (known to the general public as 'mad cow disease') in cattle, and CWD in cervids (Fig. 1) . Animal diseases are relatively easily transmitted within the same species, but cross-species transmissions have been documented as well. BSE is the only animal form of TSE that has been causatively linked to a disease in humans, vCJD (Refs 12, 38) . For a complete review on animal prion disease, see Collinge (Ref. 39) .
It is widely accepted that the causative agent of TSEs is the prion, which is mainly composed of a misfolded, insoluble, and proteinase K (PK)-resistant protein that is devoid of detectable informational nucleic acid, herein referred to as PrP TSE (also known as PrP . The exact mechanism(s) of PrP TSE generation are not fully understood. According to the current state of knowledge, the main event is the conformational change of PrP C into PrP TSE . This transition occurs under unknown circumstances and gives rise to multiple conformers exhibiting a range of strain-specific phenotypes in afflicted hosts (Ref. 41) . Temporal and spatial deposition of PrP TSE coincides with a series of pathological events in the brain, resulting in spongiform degeneration, neuronal loss, and gliosis, which constitute the hallmarks of TSEs (Ref. 42) . Prions utilise several routes of infection, which determine the length of the silent incubation period in an infected host. Usually, peripheral extra-neural exposures result in incubation phases that are longer than direct intracerebral routes. Factors and mechanisms underlying prion intra-and inter-species transmission leading to neurodegeneration are still under study, but significant progress has been made in the three decades following their discovery.
PrP
C function PrP C is a sialoglycoprotein of 253 amino acids (human PrP C ) encoded by a single gene. Post-translational processing in the endoplasmic reticulum (ER), results in the removal of an amino (N)-terminal signal sequence peptide (residues 1 to 22), and a carboxi (C)-terminal sequence for the attachment of a glycosyl phosphatidyl inositol (GPI) anchor to Ser-231 (Ref. 43) . The N-terminal domain of the protein contains a repetitive sequence (residues 52-91) of eight amino acids, the so-called octapeptide repeats (PHGGGWGQ) that appear five times in most mammalian species, a neurotoxic domain or central region (CR) (residues , and a hydrophobic domain (residues 112-135). Additionally, PrP harbours a disulphide bridge linking residues Cys-179 and Cys-214, and two glycosylation sites at residues Asn-181 and Asn-197 (human PrP C numbering) (Refs 44, 45). Nuclear magnetic resonance spectroscopy analyses of fulllength recombinant murine and hamster PrP C indicate that the secondary structure of the protein consists of a globular domain (residues 126-226) containing three α-helices, two β-strands, and a short helix-like segment comprising residues 222-226, a flexible random-coiled like N-terminal tail spanning residues 23-125, and a disordered C-terminal region (residues 227-231) (Refs 44, 46, 47) .
The physiological role of PrP C is still under debate, and defining its cellular role is complicated by the lack of major anatomical or developmental defects observed in early studies with PrP C -null (PrP −/− ) mice generated after germline genetic ablation of PrP C expression (Refs 48, 49 
136). While discrepancies in the contribution of PrP
C to AD pathogenesis may have arisen from differences in the animal models and Aβ preparations employed, all these studies suggest that the prion protein binds oAβ. Further investigations will clarify the interrelationship of both proteins and neurodegeneration.
Neurodegeneration pathways in prion disease
Owing to the temporal and spatial coincidence of PrP TSE accumulation and the appearance of the first neurodegenerative changes in the brain, it has been suggested that either the loss of a critical biological 
Molecular and cellular mechanisms of neuronal death
With just few exceptions, TSEs are characterised at the neuropathological level by various degrees of spongiform vacuolation of the neuropil, accompanied by neuronal cell loss and gliosis, which together constitute the classic neuropathological triad of TSEs (Ref. 42) . Ultrastructural studies revealed that typical 'spongiform vacuoles' develop within neuronal elements or within myelinated axons or myelin sheaths. The origin of these vacuoles is still debated, but the prevailing view attributes their occurrence to autophagy rather than to abnormalities in membrane permeability leading to increased water retention (Refs 137, 179). Recent observations derived from the pharmacological manipulation of autophagy with either autophagy-enhancing or -inhibiting drugs showing no changes on the time course or amplitude of neuronal death in response to TPrP exposure, strongly suggested that the observed autophagy in protein misfolding diseases is a secondary mechanism in the neurodegenerative process (Ref.
Autophagy in prion diseases
Basal autophagy plays an important role in maintaining cell homeostasis and physiological function. It is characterised by the formation of cytoplasmic autophagic vacuoles that fuse with lysosomes to degrade and recycle the vesicular content. This is a tissue-specific, tightly regulated process mediated via the lysosomal degradation pathway. Alternatively, autophagy induced by various cellular insults is recognised as one of the three mechanisms of programmed cell death in eukaryotes (Ref. 180). Autophagic vacuoles have been identified in several neurodegenerative diseases, including various forms of TSEs (Refs 181, 182, 183). Since, under normal conditions, autophagy takes place at low levels in the CNS an increase in the number of autophagosomes in prioninfected brains was interpreted by some as cause of neurodegeneration (Refs 170, 184, 185). However, based on recent studies providing evidence that
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vivo studies where Tg(PrP-A116V) mice, a model of GSS, were chronically treated with i.p. injections of rapamycin. Drug treatment led to a dose-dependent delay in disease onset, a reduction in symptom severity, and improved survival concomitant with increased levels of the autophagy-specific marker LC3-II (microtubule-associated protein 1A/1B-light chain 3-phosphatidylethanolamine conjugate), reduced levels of insoluble PrP-A116V, and a near to complete absence of PrP amyloid plaques in the brain. However, despite the reported reduction in amyloid burden, these mice eventually reached terminal levels of motor impairment and succumbed to the disease (Ref. 192 ).
Role of apoptosis in TSEs
Not all histopathological changes identified in TSEaffected brains can be attributed to the activation of cellular autophagy. Indeed, several studies conducted in natural disease and experimental models of TSEs observed DNA fragmentation and the activation of several caspases, indicating that neuronal death may occur via apoptotic pathways ( Refs 193, 194, 195) .
The mitochondrial pathway. This was identified in experimental models where aggregated PrP peptides, like PrP106-126, or recombinant mutant PrP were used ( Refs 196, 197, 198) . These toxic forms of PrP caused alterations in the mitochondrial membrane leading to mitochondrial stress, cytochrome c release, caspase activation, and ultimately, neuronal death (Fig. 2, solid black line) . Early findings suggested that cerebellar granule neurons (CGNs) in Tg(PG14) mice died via a Bax-dependent process ( Refs 115, 199) . However, crossing these animals with Bax −/− mice had no effect on disease onset and duration. Additionally, despite Bax inactivation significantly inhibited apoptotic death of CGNs, it did not rescue synaptic degeneration and did not prevent neurological disease. Instead, these findings supported synaptic degeneration, and not apoptotic neuronal loss, as the primary pathologic event contributing to the clinical signs observed in this model (Ref. 115) . Experiments with Bax deficient mice provided additional evidence against the primary role of proapoptotic Bax in neuronal cell death. Inoculation of Bax −/− and wild-type control mice with mouse-adapted BSE prions showed no differences in terms of PrP TSE accumulation, neurodegeneration, disease onset and clinical signs, providing compelling evidence that Bax-mediated cell death was not involved in the pathological mechanism induced by BSE (Ref. 200) . Nevertheless, cleaved caspase-3 and -9 were found in the brains of Bax −/− mice, suggesting that apoptosis may occur through an alternative mechanism in TSEs of infectious origin. These observations were consistent with previous findings of apoptotic features in the brains of wild-type mice infected with RML, in the absence of Bax upregulation (Ref. 201 ). More recently, proteomic analyses of wild-type mice injected with the same agent revealed upregulation of proteins involved in cell death and survival; in particular, in the levels of proteins associated with the mitochondrial inner membrane, proteins associated with the ubiquitin/proteasome pathway, and proteins involved in the ERAD (Ref. 178 ), but not in the brains of RML-infected Tg44 mice. This evidence further supported the notion that distinct pathways may be activated in TSEs of different aetiology.
The endoplasmic reticulum pathway. ER stress has been recently discovered as a novel apoptotic-regulatory pathway, with implications in β-amyloid cytotoxicity (Ref. 202 (Fig. 2, dashed black line) . Consistently, disruption in the expression of proteins involved in Ca 2+ homoeostasis and synaptic vesicle transport were also found in Tg44 mice with CAA (Ref. 178 ).
Other mechanisms of neurodegeneration
The studies described above suggest that autophagy and apoptosis are rather a secondary consequence of prion-induced neurodegeneration. To better understand the mechanism behind this process many laboratories have hypothesised alternative pathways triggering neurodegeneration based on other pathophysiological changes observed in the cell. (Fig. 2, dotted grey line) .
Transgenic mice expressing PrP C harbouring a deletion within the highly conserved CR of the protein, residues 105-125 (PrPΔCR) (murine PrP numbering), have been generated in an attempt to define the PrP (Fig. 2) .
The preemptive quality control (pQC) system. To further explain the necessity of a continuous supply of PrP There are three mechanisms by which proteins may be degraded in the cytosol: failed targeting, retrotranslocation and pQC. However, only the pQC pathway is activated under ER stress. There is no evidence that PrP C is synthesised in the cytosol or is retrotranslocated from the ER during normal and stress conditions (Ref. 216) . In light of these data, it has been suggested that PrP TSE accumulation triggers ER stress. Consequently, PrP C is no longer translocated into the ER but rapidly degraded by the pQC pathway. Persistent, accelerated routing of PrP C through the pQC results in neuronal damage and corresponding clinical symptoms by an unknown mechanism (Ref. 214) (Fig. 2, dotted grey double lines) .
Since the model did not fully recapitulate all clinical and histopathological changes found in prion diseases, it was proposed that several pathways lead to neurodegeneration in these disorders, including increased production of transmembrane forms of PrP ( Ctm PrP), decreased proteasome activity, or generation of a toxic intermediate during prion conversion (Ref. 214 ).
The UPR. UPR activation is a cellular response to reestablish homeostasis by synthesis of properly folded proteins. It affects the expression of chaperones, enhances degradation of unfolded and mutated proteins, and inhibits protein synthesis (Ref. 217) . When the concentration of unfolded proteins in the lumen reaches a threshold, a set of intracellular signal transduction pathways involving three transmembrane ERresident signalling components, namely inositol requiring enzyme 1 (IRE1), activating transcription factor 6 (ATF6) and double-stranded RNA-activated protein kinase (PKR)-like ER kinase (PERK), is activated. Prolonged activity of the UPR is indicative of chronic ER stress and results in cellular apoptosis (Refs 217, 218).
IRE1, a bifunctional transmembrane kinase-endoribonuclease protein, initiates the nonconventional splicing of mRNA to propagate the UPR signal (Refs 217, 219). Activated IRE1 facilitates generation of an active form of the X-box binding protein 1 (XBP-1), a UPR-specific transcription factor that enhances the transcription of UPR genes involved in protein quality control, and activates ERAD among other targets (Ref. 220) (Fig. 2 dotted black line) . While early in vitro studies in N2a cells indicated a protective role for UPR activation against PrP C misfolding under ER stress mediated by XBP-1 (Ref. 219) , infection of conditional XBP-1 knockout mice with prions demonstrated that ablation of this gene had no effect on neuronal function and prion pathogenesis in vivo, providing compelling evidence against the hypothesised neuroprotective role of the XBP-1 branch of the UPR (Ref. 221) .
Later studies in PrP C overexpressing Tg37 MloxP transgenic mice explored the involvement of the arm of the UPR responsible for translational control. This mechanism is directed by PERK phosphorylation of the ubiquitous eukaryotic translation initiation factor 2 (eIF2α) (Fig. 2 , solid black double lines) (Ref. 222) . Upon ER stress, PERK aggregates and phosphorylates itself and eIF2α (PERK-P and eIF2α-P). Phosphorylation inactivates eIF2α, and inhibits mRNA translation, therefore reducing the protein load in the ER to alleviate ER-stress (Ref. 217). However, sustained elevation of eIF2α-P leads to a decline in global translation rates and loss of synaptic proteins, contributing to neuronal death. Importantly, increased levels of PERK-P and eIF2α-P were detected throughout the course of the disease in RML-infected Tg37 mice (Ref. 222 ). Reduction of eIF2α-P levels by lentiviral-induced overexpression of GADD34, an eIF2α-Pspecific phosphatase, or inhibition of PrP C expression by anti-PrP shRNA, rescued the pathologic phenotype and significantly increased mouse survival (Ref. 222) . In contrast, pharmacological inhibition of eIF2α-P dephosphorylation further enhanced neurotoxicity and significantly accelerated the disease (Ref. 222) . These data strongly supported the conclusion that chronic UPR stress, with persistent expression of eIF2α-P and continuing inhibition of protein synthesis, leads to synaptic failure, spongiosis and neuronal loss in TSEs (Ref. 222 ).
The ubiquitin-proteasome system (UPS) and the aggresome. Ubiquitination is an efficient system for targeting cellular proteins for degradation. However, impairment of the proteasomal machinery can result in atypical ubiquitination of proteins and accumulation of ubiquitinated proteasomal substrates. Aberrations in the regulation of the UPS have been associated with a wide range of neurodegenerative diseases (Refs 223, 224). The 26S proteasomal complex comprises a 20S proteolytic core complexed at one or both ends with a 19S regulatory complex. The 20S proteasome is composed of 14 α and 14 β subunits arranged in four stacked rings, the two outer rings consisting of 7 α units and the two inner rings of 7 β subunits each. This organisation gives the 20S proteasome the appearance of a hollow barrel. Under physiological conditions, a small fraction of PrP C undergoes ubiquitination and proteasomal degradation (Ref. 225) . Positive ubiquitin staining of proteins was found in brains of CJD patients and experimental scrapie-infected mice (Refs 226, 227) . In humans afflicted with CJD, extensive aggregated deposits of PrP TSE frequently co-localise with ubiquitin, while fine granular deposits do not appear to be ubiquitinated (Ref. 228) . The notion that in scrapie-infected mice protein ubiquitination increased during infection while proteasomal activity declined, led to the suggestion that ubiquitination occurs after the formation of protease-resistant PrP TSE (Ref. 229) (Fig. 2 , dash-dotted grey line). Studies using scrapie-infected N2a cells showed that PrP Nicotine adenine dinucleotide (NAD + ) starvation. Following up on the empirical observation that changes in the composition of culture medium delayed neuroblastoma cell death after exposure to TPrP, Zhou and colleagues identified NAD + starvation as a novel mechanism of neuronal death in protein misfolding neurodegenerative diseases (Fig. 2, Reduction of eIF2α-P levels by lentiviral-induced overexpression of an eIF2α-P specific phosphatase, rescued the pathologic phenotype associated with sustained translational repression during ER stress, and significantly increased mouse survival in scrapie infected Tg37 transgenic mice (Ref. 222 ). Moreover, pharmacological modification of the UPR by selectively inhibiting PERK phosphorylation and activity upstream of eIF2α, prevented translational repression with subsequent neuroprotection. The concomitant pancreatic toxicity observed in treated mice, which led to significant body weight loss and a mild increase of glucose levels in blood, questioned the clinical application of UPR inhibitors and stimulated the search for new compounds with reduced toxicity (Ref. 239) . Additional studies from the same group identified the small molecule ISRIB (integrated stress response inhibitor), which prevents translation inhibition downstream of eIF2α-P, as a good drug candidate. Daily intraperitoneal administration of ISRIB to prion infected Tg37 +/− mice from 7 weeks post infection, showed that partial restoration of global translation rates sufficed to confer neuroprotection in the absence of pancreatic toxicity. Notably, despite significantly increasing mouse survival as compared to untreated controls, ISRIB administration resulted in significant body weight loss similarly to PERK inhibition (Ref. 240) . Understanding whether the observed weight loss results from UPR inhibition, it is a side effect of ISRIB treatment, or else it arises as a consequence of persistent prion infection will have important implications in the clinical implementation of this and similar drugs (Ref. 240) .
One of the most promising therapies for treating human prion diseases is passive immunisation with anti-PrP antibodies (Refs 241, 242) . This strategy has been extended to several neurodegenerative diseases, including TSEs, encouraged by the observed reduction in amyloid plaque burden in a transgenic mouse model of AD treated with Aβ-directed antibodies (Ref. 243 ). Additionally, several in vitro studies demonstrate the feasibility of this approach to cure or prevent cellular infection with several strains of prions (Refs 244, 245) . Importantly, a recent in vivo study demonstrated PrP TSE clearance, and increased survival, after passive immunisation with anti-PrP monoclonal antibodies administered before disease onset (Ref. 246 ). These findings indicate that therapeutic treatments aiming at blocking the conversion mechanism leading to PrP TSE generation are good approaches to treating prion diseases. Nonetheless, the practical application of these therapies depends upon the development of reliable diagnostic tests to allow early antibody administration.
Active immunisation has been evaluated in a number of studies with highly encouraging outcomes [reviewed in (Refs 241, 242) ]. Initial studies with bacteriallyexpressed recombinant full length PrP C and various PrP peptides served to highlight the difficulty in breaking tolerance to a self-protein. Additionally, they stressed the importance of breaking tolerance to raise antibodies interfering with PrP TSE replication and propagation, while at the same time, minimising an autoimmune response (Ref. 241) . Along these lines, mucosal immunisation using bacterial vectors has been suggested as an ideal means to achieve immunomodulation by inducing a secretory IgA response with limited systemic IgG levels, and minimal autoimmune inflammatory effects. This approach was validated in vivo when wild-type mice previously immunised with a mouse PrP C -expressing attenuated Salmonella strain, showed resistance to orally administered prions. These mice were characterised by significant anti-PrP mucosal IgA and systemic anti-PrP IgG response (Ref. 247) . Mucosal immunisation to prevent CWD infection has also been attempted. White-tailed deer immunisation with attenuated Salmonella expressing deer-PrP C resulted in increased titers of anti-PrP IgG and IgM in the plasma, and anti-PrP IgA in saliva and faeces as compared with control deer, showing for the first time the generation of humoral responses against self-PrP in the biological fluids of large cervid animals (Refs 241, 248). Vaccinated deer had a significantly prolonged incubation period than control animals following oral infection with a 100% lethal dose of CWD prions. One deer in the vaccinated group remained free of CWD symptoms and PrP TSE for 3 years and 7 months, as determined by immunohistochemical evaluation of tonsil and rectoanal mucosa-associated lymphoid tissue biopsies. Importantly, this animal showed the highest levels of mucosal and systemic immune response (Ref. 248) .
This study revealed the feasibility of utilising bacterial vectors to induce mucosal immunisation and prevent prion disease infection, albeit being at an early stage of development. Mucosal immunisation represents an important approach to prevent acquired forms of TSE in humans (vCJD), and interrupt transmission of BSE, scrapie, and CWD in animals in which the gut is the major route of entry. Additionally, monoclonal antibodies produced in vaccinated animals could be isolated and used for passive immunisation, extending the potential clinical application of these approaches to other forms of TSE of different aetiology (Ref. 241) .
The recent discovery of NAD + starvation as potential cause of neuronal death, led to the therapeutical investigation of NAD + replenishment in in vivo models of mouse scrapie. Stereotaxic injections of TPrP in the presence or absence of NAD + resulted in TPrP toxicity abrogation in a dose-dependent manner (Ref. 191) . When NAD + was intra-nasally administered at disease onset, mice infected with RML, showed slower disease progression and weight loss than phosphate-buffered saline (PBS)-treated control mice. A similar result was obtained when RML-infected mice were treated during the clinical phase of the disease. Although no differences in survival were observed between treated and control groups, NAD + administration significantly increased motor function in mice (Ref. 191) .
Concluding remarks
Prion diseases are devastating disorders of the CNS. At the present time there is no efficient treatment or cure for these diseases, and therefore, affected individuals die within months after the first clinical symptoms appear. Identification of the neurotoxic molecule(s) and the cellular pathways leading to neurodegeneration would facilitate the development of new therapies. Likewise, development of early, noninvasive diagnostic tests is extremely important; epidemiologically, to prevent secondary transmissions, and therapeutically, to allow the administration of effective therapies before extensive brain damage takes place. This is of particular relevance in the case of hereditary/genetic forms of TSE.
Understanding the biology underlying prionmediated neurotoxicity is challenging given the unprecedented nature of the infectious agent. PrP TSE replicates by conferring its aberrant conformation onto a cellular protein, PrP C . Studies conducted with PrP −/− mice indicated that loss of PrP C function cannot account for prion neurotoxicity, as these mice show neither a deleterious phenotype nor altered lifespan. Experimental evidence has been accumulated demonstrating the dissociation between PrP C to PrP TSE conversion with accumulation of the latter and neurotoxicity. While PrP C expression is prerequisite for prion neuroinvasion and propagation, its requirement at the neuronal membrane for neurotoxicity is still matter of controversy. Intriguing is the fact that astrocytes are refractory to TPrP toxicity, similarly to findings derived from the post-natal removal of PrP C expression highlighted above. These observations suggest that the neurotoxic entity, namely TPrP or PrP L , should be generated within neurons to cause toxicity to these cells. Importantly, the confirmation of these hypotheses relies on the successful isolation of these molecules from naturally or experimentally induced TSE; task that remains highly elusive.
Similarly controversial is the nature of the entity responsible for the neurotoxic cascade observed in TSEs. Whether prion-related neurodegeneration is triggered by the gain of toxic function of low molecular weight PrP TSE oligomers, the generation of toxic intermediates, or the subversion of PrP C biological function remains to be elucidated. But in light of the heterogeneity in clinical and pathological presentation of this diverse group of disorders, it is very likely that distinct mechanisms are involved in TSE forms of different aetiology.
Altogether, the findings described in this review indicate that significant progress has been made in recent years towards the elucidation of prion-induced mechanisms of neurodegeneration and, more importantly, potential treatments to halt these devastating disorders. Further confirmation of these mechanisms can be accomplished by refining the identification of the molecules involved in the cellular pathways activated during neurodegeneration. Genetic and biochemical methods can be utilised to identify more precisely cellular partners interacting with variants of PrP molecules, and may reveal signalling cascades activated in TSEs and other neurodegenerative diseases that culminate in neuronal death. The involvement of identified partners will subsequently need to be validated in in vitro (cell cultures, organotypic slices, mini brains) and in vivo models of prion disease. This can be accomplished, for example, by deleting the expression of the identified molecules in cells or in mice and by creating double-knockout mice and evaluating the pathologic process under these conditions. Eventually, based on findings derived from these studies, appropriate early diagnostics and targeted treatments can be developed and implemented in real life to treat humans and animals.
